The FDA has approved Arymo ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Arymo ER will be available in doses 15 mg, 30 mg, and 60 mg doses. Like other opioids, Arymo ER comes with many risks such as addiction, abuse, and misuse. Extended-release opioids such as Arymo ER also come with greater risks of overdose and death, and should only be used for patients where alternative treatments options are ineffective.
For more information on Arymo ER, read the FDA’s approval letter.